Journal of Clinical Oncology
Articles in this Issue
Aggressive variants and clinical patterns of progression in real-world metastatic hormone-sensitive prostate cancer (mHSPC).
118 Background: With the evolving treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC), including a...
Clinical outcomes of patients with grade group 1 prostate cancer with extraprostatic extension: Results from up to 25 years of follow-up.
387 Background: Grade Group 1(GG1) prostate cancer is typically an indolent disease; however, there are reports of non-org...
Triplet therapy with ADT, darolutamide, and biweekly docetaxel for high-risk metastatic castration-sensitive prostate cancer (TRIC): An open-label, single-arm phase II clinical trial.
TPS272 Background: Treatment strategies for metastatic castration-sensitive prostate cancer (mCSPC) have evolved substanti...
Prognostic and genomic implications of HER2 expression in metastatic prostate cancer.
252 Background: Evidence regarding the prevalence and clinical or biological relevance of Her2 expression in metastatic pr...
The Prolaris test on diagnostic biopsy for localized prostate cancer prognosis across risk groups and management: An individual participant data meta-analysis.
394 Background: Tools to risk stratify localized prostate cancer are limited. We sought to conduct a robust, individual pa...
PAM50 intrinsic subtyping and Decipher genomic classifier in biochemically recurrent prostate cancer after prostatectomy: Implications for ADT selection.
390 Background: PAM50 captures prostate cancer lineage (Luminal B vs Non-Luminal B [Luminal A + Basal]) and may inform res...
Shifting 177Lu-PSMA-617 upstream in mCRPC: A meta-analysis of randomized trials stratified by taxane exposure.
199 Background: 177Lu-PSMA-617 is approved for post taxane, post ARPI mCRPC based on the VISION trial. With the emergence...
Mortality risk with androgen receptor pathway inhibitors: Real-world evidence.
64 Background: Androgen deprivation therapy (ADT) is the standard of care in advanced prostate cancer (PCa). In recent yea...
Comparison of multiparametric prostate MRI (mpMRI) vs. positive biopsy cores on risk of adverse pathologic outcomes after radical prostatectomy (RP) in Gleason grade group (GG) 2 prostate cancer.
320 Background: Current guidelines endorse prognostication with percentage of positive biopsy cores when deciding upon def...
A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.
TPS894 Background: UC is the 2nd most common genitourinary cancer. Enfortumab vedotin (EV) + pembrolizumab became a SOC in...
A randomized phase 2 trial of nivolumab, relatlimab plus ipilimumab vs. nivolumab plus ipilimumab in first-line advanced renal cell carcinoma.
TPS580 Background: Ipilimumab plus nivolumab (ipi/nivo) is a standard of care for treatment-naïve, metastatic clear cell r...
Real-world evaluation of olaparib combined with novel hormone therapy in metastatic castration-resistant prostate cancer with intraductal adenocarcinoma.
213 Background: Intraductal adenocarcinoma of the prostate (IDC-P) is an aggressive histological variant of prostate cance...
SWOG 2427: Single arm phase II study of bladder preservation with immunoradiotherapy after a clinically meaningful response to neoadjuvant therapy in patients with muscle invasive bladder cancer (BRIGHT).
TPS913 Background: A subset of patients with MIBC who receive neoadjuvant therapy (NAT) prior to radical cystectomy (RC) h...
Evaluation of toxicity profiles of next-generation androgen receptor pathway inhibitors in the geriatric population: Analysis of the FAERS (FDA Adverse Event Reporting System) database.
206 Background: The use of next-generation ARPIs in combination with ADT has revolutionized the treatment of prostate canc...
Regional variations in bladder cancer (BC) clinical trial availability within the United States (US).
652 Background: Geographic disparities of phase I-III cancer clinical trials in the US are well described (Gu et al., JMCP...
Circulating tumor DNA response adapted treatment de-escalation in metastatic urothelial carcinoma (CT-READ).
TPS907 Background: Metastatic urothelial carcinoma (mUC) remains a lethal disease remains an aggressive malignancy with a...
Metastatic lesion location and avidity on baseline PSMA PET/CT as predictor of duration of Lu177 treatment in men with metastatic castrate resistant prostate cancer.
188 Background: 177 Lu-PSMA-617 PSMA is a prostate-specific membrane antigen (PSMA) targeted radioliga...
National trends and disparities in bladder cancer mortality associated with tobacco use between 1999 and 2020.
656 Background: Bladder Cancer is one of the most serious types of cancer that can lead to death, especially when it’s com...
Clinical outcomes of pembrolizumab and enfortumab vedotin in variant histology urothelial carcinoma.
754 Background: Enfortumab vedotin (EV) in combination with pembrolizumab is an FDA-approved regimen for patients with loc...
Head-to-head comparison of pembrolizumab-axitinib versus pembrolizumab-lenvatinib in metastatic RCC: Real world data from the Canadian Kidney Cancer Information System (CKCis) database.
460 Background: Immune checkpoint inhibitor-tyrosine kinase inhibitor (IO-TKI) combinations have transformed first-line tr...
Prostate cancer screening uptake and predictors of elevated prostate-specific antigen levels in Southwestern Nigeria.
403 Background: Prostate cancer is the most commonly diagnosed malignancy among men in Nigeria, yet uptake of prostate-spe...
Cyto-KIK: A phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib).
513 Background: Despite recent therapeutic advancements in metastatic clear cell renal cell carcinoma (mccRCC), only about...
Representation of Latin American oncologists in oral sessions at the ASCO Genitourinary Cancers symposium: A five-year review (2021–2025).
44 Background: Latin American (LATAM) investigators contribute substantially to global genitourinary (GU) cancer research...
Circulating tumor DNA kinetics as a biomarker of response to enfortumab-pembrolizumab in advanced urothelial carcinoma.
703 Background: The association of circulating tumor DNA (ctDNA) reduction with treatment response has been investigated a...
Safety and efficacy of pasritamig (PAS) + docetaxel (DOCE) in participants with metastatic castration-resistant prostate cancer (mcrPc): Initial results of a phase 1b study.
171 Background: DOCE is a standard of care for pts with mCPRC after androgen receptor pathway inhibitor (ARPI) failure, bu...